Working… Menu

Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01708590
Recruitment Status : Terminated (Sponsor decision)
First Posted : October 17, 2012
Last Update Posted : August 24, 2015
Information provided by (Responsible Party):

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Terminated
Actual Primary Completion Date : May 2014
Estimated Study Completion Date : August 2015
Certification/Extension First Submitted : April 1, 2015
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 November 2, 2016
December 29, 2016
2 February 8, 2017
March 28, 2017
3 April 14, 2017
May 22, 2017
4 December 8, 2017
January 8, 2018